{
    "code": "10000877",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=10000877",
    "time": "2024-02-22 19:27:57",
    "許可證字號": "衛署菌疫輸字第000877號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "118\/03\/11",
    "發證\/登錄日期": "98\/03\/11",
    "許可證\/登錄種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA01000087701",
    "中文品名": "爾必得舒 注射液 5 毫克\/毫升",
    "英文品名": "Erbitux 5mg\/ml Solution for infusion",
    "適應症": "適用於治療RAS原生型(wild-type)之轉移性直腸結腸癌患者\r\n• 與FOLFIRI (Folinic acid\/ 5-FU\/ Irinotecan)合併使用之第一線治療。\r\n• 與FOLFOX合併使用之第一線治療。\r\n併用encorafenib，⽤於治療帶有BRAF V600E 突變且曾接受過治療之轉移性直腸結腸癌 (CRC) 成人病人。\r\n與放射線療法合併使用，治療局部晚期之口咽癌、下咽癌及喉癌患者。\r\n與內含platinum類之化學療法合併使用，治療復發及\/或轉移性頭頸部鱗狀細胞癌患者。",
    "劑型": "270注射劑",
    "包裝": "20毫升小瓶裝 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "CETUXIMAB, CHIMERIC ANTIBODY",
    "限制項目": "02輸　入",
    "申請商名稱": "台灣默克股份有限公司",
    "申請商地址": "台北市內湖區堤頂大道2段89號6樓",
    "主製造廠": [
        {
            "製造廠名稱": "Merck Healthcare KGaA",
            "製造廠廠址": "FRANKFURTER STRASSE 250, 64293 DARMSTADT, GERMANY",
            "製造廠公司地址": "",
            "製造廠國別": "GERMANY",
            "製程": "自濃縮原料藥(Concentrated bulk)之稀釋(Dilution或Formulation)作業至成品製劑、一級及二級包裝作業。"
        },
        {
            "製造廠名稱": "BOEHRINGER INGELHEIM PHARMA GMBH &amp; CO. KG",
            "製造廠廠址": "BIRKENDORFER STRASSE 65, 88397 BIBERACH AN DER RISS, GERMANY",
            "製造廠公司地址": "BINGER STRASSE 173, 55216 INGELHEIM AM RHEIN, GERMANY",
            "製造廠國別": "GERMANY",
            "製程": "原料藥製造廠"
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "MERCK SERONO S.A.-CORSIER-SUR-VEVEY",
            "製造廠廠址": "ROUTE DE FENIL, 25 ZONE INDUSTRIELLE B, 1804 CORSIER-SUR-VEVEY, SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "原料藥(Cetuximab)自工作細胞庫至濃縮原料藥(Concentrated bulk)之製造階段。"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013000900",
            "成分名稱": "CETUXIMAB, CHIMERIC ANTIBODY",
            "含量描述": "",
            "含量": "5.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "PIL ERBITUX 5MG-ML (0.5%)_Jun 2023 uploaded in TFDA-112-06-06(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000877&Seq=013&Type=9"
        },
        {
            "title": "1076038126-中文仿單-clean to TFDA-108-03-13.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000877&Seq=012&Type=9"
        },
        {
            "title": "TFDA upload version-FBO ERBITUX 5 MG-ML (0.5%) (1x20ml) - TW-108-08-12(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000877&Seq=009&Type=8"
        },
        {
            "title": "FBO ERBITUX 5 MG-ML (0.5%) (1x20ml) - TW-107-09-25(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000877&Seq=007&Type=8"
        },
        {
            "title": "LAB Erbitux-106-02-15.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000877&Seq=006&Type=8"
        },
        {
            "title": "FBO Erbitux Merck-106-02-15.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000877&Seq=005&Type=8"
        },
        {
            "title": "FBO Erbitux BI-106-02-15.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000877&Seq=004&Type=8"
        }
    ]
}